Clinical Rheumatology

, Volume 37, Issue 2, pp 423–428 | Cite as

Prevalence of comorbidities and evaluation of screening in Chinese patients with spondyloarthritis

  • Yutong Jiang
  • Pingping Zhang
  • Liudan Tu
  • Qing Lv
  • Jun Qi
  • Zhiming Lin
  • Zetao Liao
  • Shuangyan Cao
  • Jieruo GuEmail author
Original Article


The aim of the study was to determine whether the presence of spondyloarthritis (SpA) is associated with particular comorbidities and evaluate the prevalence of comorbidities, risk factors, and monitoring status in China. Three hundred forty-six patients fulfilling ASAS criteria for SpA were recruited from the Third Affiliated Hospital of Sun Yat-sen University. The prevalence of comorbidities and percentage of patients optimally monitored for comorbidities were calculated. The most frequent comorbidities were osteoporosis (31.0%) and hepatitis B virus infection (18.5%). Only 1 patient was found to have active tuberculosis. Several cancer screenings were performed in very few patients. Among 45 patients ever exposed to a biological DMARDs, 35 (77%) and 36 (80%) underwent a screening test for viral hepatitis and tuberculosis. Among patients without a history of hypertension, elevated blood pressure was detected in 5.8% of the patients. Hyperglycemia and hyperlipidemia were also found in patients during the study. One hundred twenty-two (35.3%) of the 346 patients never had either calcium or vitamin D for prevention of osteoporosis. Patients with SpA have high risks of comorbidities but have not monitored properly. More attention should be paid for systematic screening and an early detection of comorbidities in patients with SpA.


Comorbidities Infection Osteoporosis Spondyloarthritis 



This work was supported by the 5010 Subject of Sun Yat-sen University (2007023), National Natural Science Foundation of China Grant (31070806) and scientific technology plan projects of Guangdong Province (2014A020212435).

Compliance with ethical standards

This study was conducted in compliance with the Helsinki Declaration to protect human subjects and was approved by the Third Affiliated Hospital of Sun Yat-sen University ethics committee. All participants gave written informed consent before enrolment.



Supplementary material

10067_2017_3905_MOESM1_ESM.docx (18 kb)
ESM 1 (DOCX 17 kb)


  1. 1.
    Mathieu S, Pereira B, Soubrier M (2015) Cardiovascular events in ankylosing spondylitis: an updated meta-analysis. Semin Arthritis Rheum 44:551–555CrossRefPubMedGoogle Scholar
  2. 2.
    Wang DM, Zeng QY, Chen SB, Gong Y, Hou ZD, Xiao ZY (2015) Prevalence and risk factors of osteoporosis in patients with ankylosing spondylitis: a 5-year follow-up study of 504 cases. Clin Exp Rheumatol 33:465–470PubMedGoogle Scholar
  3. 3.
    Molto A, Etcheto A, van der Heijde D, Landewe R, van den Bosch F, Bautista MW et al (2016) Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Ann Rheum Dis 75:1016–1023CrossRefPubMedGoogle Scholar
  4. 4.
    Zeidler H, Amor B (2011) The Assessment in Spondyloarthritis International Society (ASAS) classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general: the spondyloarthritis concept in progress. Ann Rheum Dis 70:1–3CrossRefPubMedGoogle Scholar
  5. 5.
    Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J et al (2009) The development of Assessment of Spondyloarthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68:777–783CrossRefPubMedGoogle Scholar
  6. 6.
    Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291PubMedGoogle Scholar
  7. 7.
    Lukas C, Landewe R, Sieper J, Dougados M, Davis J, Braun J et al (2009) Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 68:18–24CrossRefPubMedGoogle Scholar
  8. 8.
    Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285PubMedGoogle Scholar
  9. 9.
    Munoz-Ortego J, Vestergaard P, Rubio JB, Wordsworth P, Judge A, Javaid MK et al (2014) Ankylosing spondylitis is associated with an increased risk of vertebral and nonvertebral clinical fractures: a population-based cohort study. J Bone Miner Res 29:1770–1776CrossRefPubMedGoogle Scholar
  10. 10.
    Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan RC et al (1994) Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol 152:2037–2042CrossRefPubMedGoogle Scholar
  11. 11.
    Friedrich MJ (2011) Debate continues on use of PSA testing for early detection of prostate cancer. JAMA 305:2273–2275CrossRefPubMedGoogle Scholar
  12. 12.
    Welch HG, Albertsen PC (2009) Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 101:1325–1329CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Chinese ADPC (2007) Chinese adult dyslipidemia prevention guideline. Chin J Cardio 5:390–394Google Scholar
  14. 14.
    Otsuka A, Morita M, Yamada H (2015) Clinical characteristics of Japanese patients with axial spondyloarthritis, and short-term efficacy of adalimumab. J Orthop Sci 20:1070–1077CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Cui Y, Jia J (2013) Update on epidemiology of hepatitis B and C in China. J Gastroenterol Hepatol 28(Suppl 1):7–10CrossRefPubMedGoogle Scholar
  16. 16.
    Ho HH, Lin MC, KH Y, Wang CM, YJ W, Chen JY (2009) Pulmonary tuberculosis and disease-related pulmonary apical fibrosis in ankylosing spondylitis. J Rheumatol 36:355–360CrossRefPubMedGoogle Scholar
  17. 17.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108CrossRefPubMedGoogle Scholar
  18. 18.
    Quinn M, Babb P (2002) Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int 90:162–173CrossRefPubMedGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2017

Authors and Affiliations

  • Yutong Jiang
    • 1
  • Pingping Zhang
    • 1
    • 2
  • Liudan Tu
    • 1
  • Qing Lv
    • 1
  • Jun Qi
    • 1
  • Zhiming Lin
    • 1
  • Zetao Liao
    • 1
  • Shuangyan Cao
    • 1
  • Jieruo Gu
    • 1
    Email author
  1. 1.Department of RheumatologyThe Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhouChina
  2. 2.Department of PediatricsThe Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhouChina

Personalised recommendations